ReviewLiver cancer2016
Transarterial Therapies for Hepatocellular Carcinoma.
Review in Liver cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis.Medicine · 2020Pooled it
- Characteristics of hepatocellular carcinoma in a Saudi tertiary care center: a 10-year retrospective study.Hepatic oncology · 2026Article
- Single-Cell Transcriptomics Dissects the Molecular Mechanism by Which Macrophage Polarization Drives Hepatocellular Carcinoma Metastasis Through Crosstalk with Emt-Tumor Microenvironment.Digestive diseases and sciences · 2026Article
- Recent advances in nanomaterial-based precision medicine for orthotopic tumor therapy.Journal of nanobiotechnology · 2026Review
- Magnesium microspheres for enhanced transarterial chemoembolization therapy of hepatocellular carcinoma: From animal models to a pilot clinical study.Science advances · 2025Article
- Beyond Conventional CT: Role of Dual-Energy CT in Monitoring Response to Therapy in Abdominal Malignancies.Radiology. Imaging cancer · 2025Review
- Adjusted Tumor Enhancement on Dual-Phase Cone-Beam CT: Predictor of Response and Overall Survival in Patients with Liver Malignancies Treated with Hepatic Artery Embolization.Current oncology (Toronto, Ont.) · 2024Article
- The efficacy and safety of lenvatinib plus transarterial chemoembolization in combination with PD-1 antibody in treatment of unresectable recurrent hepatocellular carcinoma: a case series report.Frontiers in oncology · 2023Article
- The Antitumor Impact of Combining Hepatic Artery Ligation With Copper Chelators for Liver Cancer.Clinical Medicine Insights. Oncology · 2023Article
- Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.Cancer biology & therapy · 2022Article
- Targeted blocking of CCR2 and CXCR2 improves the efficacy of transarterial chemoembolization of hepatocarcinoma.Cancer cell international · 2022Article
- A pure nanoICG-based homogeneous lipiodol formulation: toward precise surgical navigation of primary liver cancer after long-term transcatheter arterial embolization.European journal of nuclear medicine and molecular imaging · 2022Article
- Article
- Comparison of radiation doses between hepatic artery infusion chemotherapy and transarterial chemoembolization for liver cancer.Journal of interventional medicine · 2021Article
- Maximum Plasma Concentration of Lenvatinib Is Useful for Predicting Thrombocytopenia in Patients Treated for Hepatocellular Carcinoma.World journal of oncology · 2021Article
- Article
- Interplay of autophagy and cancer stem cells in hepatocellular carcinoma.Molecular biology reports · 2021Review
- Article
- High expression of theJournal of gastrointestinal oncology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of hepatocellular carcinoma (HCC) is still a major health issue because of its increasing incidence and because of the complexity of its management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of HCC, especially for unresectable intermediate and advanced HCCs. SUMMARY: The modern use of TAE and TACE opens new scenarios for the treatment of unresectable HCC and has yielded interesting results. The present work describes the role of transarterial therapies for HCC and focuses on the different Western and Eastern approaches to the study of response predictors. KEY MESSAGES: Recent refinements in interventional radiology techniques and in HCC patient selection have facilitated better local control of the disease. The molecular profiling of HCC to predict the response to TACE and TAE will greatly help clinicians identify the optimum therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.